KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Deferred Revenue (2016 - 2023)

Historic Current Deferred Revenue for Halozyme Therapeutics (HALO) over the last 15 years, with Q3 2023 value amounting to $2.9 million.

  • Halozyme Therapeutics' Current Deferred Revenue fell 5451.0% to $2.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.9 million, marking a year-over-year decrease of 5451.0%. This contributed to the annual value of $5.5 million for FY2022, which is 2860.15% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Current Deferred Revenue stood at $2.9 million for Q3 2023, which was down 5451.0% from $3.1 million recorded in Q2 2023.
  • In the past 5 years, Halozyme Therapeutics' Current Deferred Revenue ranged from a high of $6.9 million in Q2 2022 and a low of $1.4 million during Q2 2020
  • In the last 5 years, Halozyme Therapeutics' Current Deferred Revenue had a median value of $4.7 million in 2020 and averaged $4.4 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Current Deferred Revenue plummeted by 7866.69% in 2020 and then surged by 27962.56% in 2021.
  • Over the past 5 years, Halozyme Therapeutics' Current Deferred Revenue (Quarter) stood at $5.3 million in 2019, then crashed by 66.8% to $1.7 million in 2020, then surged by 144.9% to $4.3 million in 2021, then grew by 28.6% to $5.5 million in 2022, then crashed by 46.9% to $2.9 million in 2023.
  • Its Current Deferred Revenue stands at $2.9 million for Q3 2023, versus $3.1 million for Q2 2023 and $5.5 million for Q1 2023.